Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

Richard P. Baum; Christiane Schuchardt; Aviral Singh; Maythinee Chantadisai; Franz C. Robiller; Jingjing Zhang; Dirk Mueller; Alexander Eismant; Frankis Almaguel; Dirk Zboralski; Frank Osterkamp; Aileen Hoehne; Ulrich Reineke; Christiane Smerling; Harshad R. Kulkarni

doi:10.2967/jnumed.120.259192

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, Franz C. Robiller, Jingjing Zhang, Dirk Mueller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Harshad R. Kulkarni

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	415-423
Number of pages	9
Journal	Journal of Nuclear Medicine
Volume	63
Issue number	3
DOIs	https://doi.org/10.2967/jnumed.120.259192
State	Published - Mar 1 2022

ASJC Scopus Subject Areas

Radiology Nuclear Medicine and imaging

Keywords

177Lu-FAP-2286
adenocarcinoma
fibroblast activation protein
first-in-humans
peptidetargeted radionuclide therapy

Access to Document

10.2967/jnumed.120.259192

OpenUrl availability

Full text

Cite this

Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F. C., Zhang, J., Mueller, D., Eismant, A., Almaguel, F., Zboralski, D., Osterkamp, F., Hoehne, A., Reineke, U., Smerling, C., & Kulkarni, H. R. (2022). Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. Journal of Nuclear Medicine, 63(3), 415-423. https://doi.org/10.2967/jnumed.120.259192

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. / Baum, Richard P.; Schuchardt, Christiane; Singh, Aviral et al.
In: Journal of Nuclear Medicine, Vol. 63, No. 3, 01.03.2022, p. 415-423.

Research output: Contribution to journal › Article › peer-review

Baum, RP, Schuchardt, C, Singh, A, Chantadisai, M, Robiller, FC, Zhang, J, Mueller, D, Eismant, A, Almaguel, F, Zboralski, D, Osterkamp, F, Hoehne, A, Reineke, U, Smerling, C & Kulkarni, HR 2022, 'Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results', Journal of Nuclear Medicine, vol. 63, no. 3, pp. 415-423. https://doi.org/10.2967/jnumed.120.259192

@article{488d1a4374444b8eb9a093e9749ff4fe,

title = "Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results",

keywords = "177Lu-FAP-2286, adenocarcinoma, fibroblast activation protein, first-in-humans, peptidetargeted radionuclide therapy",

author = "Baum, {Richard P.} and Christiane Schuchardt and Aviral Singh and Maythinee Chantadisai and Robiller, {Franz C.} and Jingjing Zhang and Dirk Mueller and Alexander Eismant and Frankis Almaguel and Dirk Zboralski and Frank Osterkamp and Aileen Hoehne and Ulrich Reineke and Christiane Smerling and Kulkarni, {Harshad R.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the Society of Nuclear Medicine andMolecular Imaging.",

year = "2022",

month = mar,

day = "1",

doi = "10.2967/jnumed.120.259192",

language = "English",

volume = "63",

pages = "415--423",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

number = "3",

}

TY - JOUR

T1 - Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286

T2 - First-in-Humans Results

AU - Baum, Richard P.

AU - Schuchardt, Christiane

AU - Singh, Aviral

AU - Chantadisai, Maythinee

AU - Robiller, Franz C.

AU - Zhang, Jingjing

AU - Mueller, Dirk

AU - Eismant, Alexander

AU - Almaguel, Frankis

AU - Zboralski, Dirk

AU - Osterkamp, Frank

AU - Hoehne, Aileen

AU - Reineke, Ulrich

AU - Smerling, Christiane

AU - Kulkarni, Harshad R.

PY - 2022/3/1

Y1 - 2022/3/1

KW - 177Lu-FAP-2286

KW - adenocarcinoma

KW - fibroblast activation protein

KW - first-in-humans

KW - peptidetargeted radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=85125553283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125553283&partnerID=8YFLogxK

U2 - 10.2967/jnumed.120.259192

DO - 10.2967/jnumed.120.259192

M3 - Article

C2 - 34168013

AN - SCOPUS:85125553283

SN - 0161-5505

VL - 63

SP - 415

EP - 423

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 3

ER -

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this